Sign In
Buy CTXR
$0.580
-0.0230 (-3.81%)
At Close: Jun 03, 2026
Investigator-initiated study data presented May 30, 2026, at the American Society of Clinical Oncology (ASCO) Annual Meeting demonstrated durable responses and manageable tolerability in heavily pre-t
24% Objective Response Rate, with an average of 21.1 month Duration of Response in responders, and favorable safety profile signals potential of LYMPHIR to augment immune checkpoint inhibitor efficacy
Citius Oncology, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
04:30pm, Friday, 15'th May 2026
$5.6 million in net revenue for the first half of fiscal 2026 as LYMPHIR ® launch progresses Up to $36.5 million in debt and equity capital secured Broad payer coverage established with no reimbursem
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update
04:30pm, Friday, 15'th May 2026
$5.6 Million in net revenue for the first half of fiscal 2026 from ongoing launch of LYMPHIR ® Citius Pharma raised $5 million in a registered direct offering; Citius Oncology secured up to $36.5 mil
Citius Oncology Ships First International Order of LYMPHIR™ to Europe
08:00am, Wednesday, 29'th Apr 2026
Order fulfilment expands international patient access to LYMPHIR following initial U.S. launch Distribution by regional partners through Named Patient Programs in specific international markets CRANFO
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
04:30pm, Friday, 24'th Apr 2026
CRANFORD, N.J., April 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercializa
What's Behind The Drop In Citius Pharmaceuticals?
10:47am, Friday, 24'th Apr 2026
Citius Pharmaceuticals (NASDAQ:CTXR) shares tumbled on Friday after the company announced a registered direct offering, a financing move that often pressures micro-cap biotech stocks due to dilution c
Citius Pharmaceuticals Announces a Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules
08:00am, Friday, 24'th Apr 2026
CRANFORD, N.J., April 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius Pharma" or the "Company"), a biopharmaceutical company dedicated to the development and commercializa
Citius Oncology Provides Commercial Update on LYMPHIR™ Launch Highlighting Early Adoption and Expanding Clinical Development
09:11am, Tuesday, 31'st Mar 2026
Broad institutional uptake among leading cancer centers and payer coverage supports early prescribing momentum and clinical integration CRANFORD, N.J., March 31, 2026 /PRNewswire/ -- Citius Oncology,
Citius Pharmaceuticals (NASDAQ:CTXR) and Klotho Neurosciences (NASDAQ:KLTO) Head-To-Head Comparison
01:15am, Saturday, 28'th Mar 2026
Klotho Neurosciences (NASDAQ: KLTO - Get Free Report) and Citius Pharmaceuticals (NASDAQ: CTXR - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contras
Citius Oncology to meet with cutaneous T-cell lymphoma (CTCL) specialists as part of ongoing clinical engagement; one-on-one meetings available CRANFORD, N.J., March 24, 2026 /PRNewswire/ -- Citius On
Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Topline data of University of Pittsburgh-led t
Topline data of investigator‑initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% complete response (CR) and 29% partial respons
Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program
08:00am, Tuesday, 24'th Feb 2026
Non-dilutive capital supports continued execution and value creation CRANFORD, N.J., Feb. 24, 2026 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a bio
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
08:00am, Friday, 13'th Feb 2026
Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results CRANFORD, N.J., Feb. 13, 2026 /PRNewswire/ -- Citius Onco
